TaiGen Biopharmaceuticals Holdings Limited (TPEX:4157)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
12.35
+0.05 (0.41%)
Feb 26, 2026, 1:30 PM CST
5.56%
Market Cap 8.79B
Revenue (ttm) 38.75M
Net Income (ttm) -184.20M
Shares Out 711.83M
EPS (ttm) -0.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,022,255
Average Volume 3,946,796
Open 12.30
Previous Close 12.30
Day's Range 12.20 - 12.40
52-Week Range 7.44 - 16.40
Beta 0.29
RSI 38.99
Earnings Date Mar 13, 2026

About TPEX:4157

TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. Its product pipeline comprises Taigexyn, which is in phase II clinical trial for the treatment of community-acquired pneumonia/diabetic foot infection; TG-1000, which is in phase III clinical trial to treat influenza A and B, and avian influenza H7N9; Furaprevir, a HCV protease inhibit... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Country Cayman Islands
Stock Exchange Taipei Exchange
Ticker Symbol 4157
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.